Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180481 | 0.98 | MAOA (0.60) | MAOAHRH1HTR2ASPHK2SPHK1 | |
| SCHEMBL5966793 | 0.91 | MAOA (0.50) | MAOAHRH1HTR2ACYP3A4IDO1 | |
| SCHEMBL28284957 | 0.88 | SPHK2 (0.46) | HTR2ASPHK2SPHK1CYP3A4IDO1 | |
| SCHEMBL9350714 | 0.88 | MAOA (0.71) | MAOAHRH1HTR2A | |
| SCHEMBL3680378 | 0.85 | MAOA (0.75) | MAOAHRH1HTR2A | |
| SCHEMBL21580517 | 0.81 | MAOA (0.62) | MAOAHRH1HTR2A | |
| SCHEMBL168309 | 0.80 | TAAR1 (0.56) | HTR2ACYP3A4IDO1 | |
| SCHEMBL5243221 | 0.80 | CYP3A4 (0.46) | HTR2ASPHK2SPHK1CYP3A4IDO1 | |
| SCHEMBL11433147 | 0.79 | SPHK2 (0.41) | HTR2ASPHK2SPHK1CYP3A4IDO1 | |
| SCHEMBL6014350 | 0.79 | MAOB (0.64) | MAOAHRH1HTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0459386-A1 | Preparation of polyamides | EASTMAN KODAK COMPANY (US) | 1991-12-04 | — | — | EP | claimed |
| US-20260041797-A1 | RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041797-A1 | RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF | RAD51, BRCA1, HLA-DRB1 | MAOA 2114/4885HRH1 4498/4885HTR2A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.